Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanguinarine is a **benzophenanthridine alkaloid** natural product and **small molecule** quaternary ammonium compound isolated from plants including *Sanguinaria canadensis*, *Chelidonium majus*, and *Macleaya cordata*. It has been studied mainly in **preclinical and academic oncology research** rather than formal commercial drug development, with reported anticancer activity in models of non-small cell lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, and other tumors. Its pharmacology appears **multitarget and pleiotropic**, with published studies describing inhibition of **thioredoxin reductase**, **Aurora kinase A**, **cyclin-dependent kinase 2**, and **Akt signaling**, alongside induction of **reactive oxygen species**, mitochondrial dysfunction, cell-cycle arrest, and apoptosis. Despite this experimental antineoplastic interest, sanguinarine is **not an approved therapeutic agent**, lacks an established branded pharmaceutical program, and has important **toxicity and potential carcinogenicity concerns** that have limited clinical translation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanguinarine.